Lv5
1190 积分 2025-07-27 加入
不明原发肿瘤诊疗中国专家共识（2024版）
18天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
18天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
18天前
已完结
Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges
18天前
已完结
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
26天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
1个月前
已完结
Advances in systemic therapies for triple negative breast cancer
1个月前
已完结
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
1个月前
已完结
皖公网安备34019202002308
